We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including Multiple Sclerosis. AZADYNE originated from cutting-edge research from the laboratories of Profs Vincent P. Kelly, Stephen Connon and J. Mike Southern of Trinity Biomedical Sciences Institute, Trinity College Dublin. Autoimmunity occurs when the body mistakenly attacks itself resulting in inflammation and damage. Over time this can lead to chronic, debilitating diseases such as Multiple Sclerosis, Rheumatoid Arthritis and Inflammatory Bowel Disease. Currently, these diseases are not curable. Our pioneering approach has identified a naturally occurring micronutrient called queuine with the ability to control autoimmune response in the body. Through novel chemistry and unique insights, AZADYNE has developed new molecules delivering improved therapeutic outcomes for patients and their families. Our candidates are on the path to Phase I or FIH trials.